SCHEMBL6943963

SCHEMBL6943963

CCCNCCC.CCN1CCC(N)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 3/20 0.47
GNAO1 P09471 3/20 0.47
GNAI1 P63096 3/20 0.47
SMN1; SMN2 Q16637 1/20 0.41
SPHK1 Q9NYA1 1/20 0.38
KDM4E B2RXH2 3/20 0.33
EPHX1 P07099 2/20 0.33
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31
CARM1 Q86X55 1/20 0.31
PRMT6 Q96LA8 1/20 0.31
PRMT1 Q99873 1/20 0.31
PRMT8 Q9NR22 1/20 0.31
DPP4 P27487 1/20 0.30
EPHX2 P34913 1/20 0.30
HSD11B1 P28845 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6947754 0.89 GNAI3 (0.53) GNAI3GNAO1GNAI1SMN1; SMN2SPHK1
SCHEMBL6941401 0.86 GNAI3 (0.55) GNAI3GNAO1GNAI1SPHK1CARM1
SCHEMBL684220 0.85
Diethylamine SCHEMBL6945162 0.83 GNAI3 (0.46) GNAI3GNAO1GNAI1SMN1; SMN2SPHK1
SCHEMBL7227686 0.83 GNAI3 (0.61) GNAI3GNAO1GNAI1SPHK1CARM1
SCHEMBL6944193 0.83 GNAO1 (0.66) GNAI3GNAO1GNAI1SPHK1EPHX1
Dimethylamine SCHEMBL6945951 0.83 GNAI3 (0.48) GNAI3GNAO1GNAI1SMN1; SMN2SPHK1
Hydrochloric Acid SCHEMBL23247778 0.83 GNAI3 (0.57) GNAI3GNAO1GNAI1SMN1; SMN2SPHK1
Hydrochloric Acid SCHEMBL3277895 0.83 GNAI3 (0.57) GNAI3GNAO1GNAI1SMN1; SMN2SPHK1
SCHEMBL28509877 0.82 ALDH1A1 (0.36) GNAI3GNAO1GNAI1KDM4EEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642231-B2 Antineoplastic agents, treatment for neuronal injury and degeneration AVENTIS PHARMACEUTICALS INC. 2003-11-04 US disclosed
EP-1056744-B1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMA INC (US) 2003-10-22 EP disclosed
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines AVENTISUB II INC. 2003-06-05 US disclosed
US-6479487-B1 INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS AVENTIS PHARMACEUTICALS INC. 2002-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines CDK6, CDK5, CDK2 GNAI3 2099/4885GNAO1 2886/4885GNAI1 2256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.